AARS sirna

AARS siRNA (Human)

Cat. Num. AAA8216528

• Gene Names: AARS; CMT2N; EIEE29
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: AARS; AARS siRNA (Human); Alanine--tRNA ligase cytoplasmic; Alanyl-tRNA synthetase; AlaRS; Renal carcinoma antigen NY-REN-42; AARS sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: AARS siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 992

• Applicable Applications for AARS sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human AARS gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for AARS sirna

siRNA to inhibit AARS expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 109148542
• NCBI GeneID: 16
• NCBI Accession #: NP_001596.2
• NCBI GenBank Nucleotide #: NM_001605.2
• UniProt Accession #: P49588; Q53GV7; Q96FA0; A6NF14; B4DR45
• Molecular Weight: 109,317 Da
• NCBI Official Full Name: alanine--tRNA ligase, cytoplasmic
• NCBI Official Synonym Full Names: alanyl-tRNA synthetase
• NCBI Official Symbol: AARS
• NCBI Official Synonym Symbols: CMT2N; EIEE29
• NCBI Protein Information: alanine--tRNA ligase, cytoplasmic
• UniProt Protein Name: Alanine--tRNA ligase, cytoplasmic
• UniProt Gene Name: AARS
• UniProt Synonym Gene Names: AlaRS
• UniProt Entry Name: SYAC_HUMAN

NCBI Description

The human alanyl-tRNA synthetase (AARS) belongs to a family of tRNA synthases, of the class II enzymes. Class II tRNA synthases evolved early in evolution and are highly conserved. This is reflected by the fact that 498 of the 968-residue polypeptide human AARS shares 41% identity witht the E.coli protein. tRNA synthases are the enzymes that interpret the RNA code and attach specific aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. They consist of a catalytic domain which interacts with the amino acid acceptor-T psi C helix of the tRNA, and a second domain which interacts with the rest of the tRNA structure. [provided by RefSeq, Jul 2008]

Uniprot Description

AARS: Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala- AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain. Defects in AARS are the cause of Charcot-Marie-Tooth disease type 2N (CMT2N). It is an axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies(designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Nerve conduction velocities are normal or slightly reduced. Belongs to the class-II aminoacyl-tRNA synthetase family.

Protein type: Translation; Ligase; RNA-binding; EC 6.1.1.7

Chromosomal Location of Human Ortholog: 16q22

Cellular Component: membrane; cytoplasm; cytosol

Molecular Function: amino acid binding; zinc ion binding; alanine-tRNA ligase activity; ATP binding; tRNA binding

Biological Process: tRNA aminoacylation for protein translation; hair follicle development; protein folding; tRNA processing; unfolded protein response; regulation of translational fidelity; cerebellar Purkinje cell layer development; gene expression; negative regulation of neuron apoptosis; response to amino acid stimulus; tRNA modification; neuromuscular process controlling balance; alanyl-tRNA aminoacylation

Disease: Epileptic Encephalopathy, Early Infantile, 29; Charcot-marie-tooth Disease, Axonal, Type 2n